This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/20/2026
Phase 2 studies evaluating the use of alternative dexamethasone dosing regimens during treatment with YONDELIS in patients with soft tissue sarcoma (STS) are summarized in the table below.
| Study Design | Dosing Regimen | Key Efficacy Results | Key Safety Results | |
|---|---|---|---|---|
| Martin-Broto et al (2016)7 | Randomized, open-label, parallel-group study in pts with locally advanced nonresectable or metastatic STS (N=115) |
Both treatments given Q3W for 6 cycles in absence of PD or unacceptable toxicity | Median f/u: 13 mo for YONDELIS + DOX vs DOX alone, respectively Primary Endpoint:
Additional Endpoints:
| Grade 3-4 AEs with significantly higher incidence with YONDELIS + DOX vs DOX alone: Bilirubin ↑ (29% vs 12%; P=0.002), asthenia (25% vs 4%; P=0.002), ALT ↑ (19% vs 0; P<0.001), thrombocytopenia (18% vs 2%; P=0.016), and AST ↑ (8% vs 0; P=0.007) Deaths: 4 (2 in each arm) involving liver/renal failure (YONDELIS + DOX, n=1) and septic shock/neutropenia (remaining 3 pts) |
| Paz-Ares et al (2012)6 | Multicenter study w/ phase 1 (double-blind, randomized, crossover) and phase 2 (pts choose +/- Dex) components in pts w/ previously treated unresectable, advanced, or metastatic STS; due to toxicity, modified to open-label w/mandatory Dex (N=41) |
| Median f/u: 21.2 mo Primary Endpoint:
Additional Endpoints:
| Grade 3-4 AEs: ALT ↑ (66%), AST ↑ (56%), neutropenia (51%), lymphopenia (51%), leukopenia (39%), vomiting (27%), anemia (22%), thrombocytopenia (22%), febrile neutropenia (15%), fatigue (12%), creatinine ↑ (7%), renal failure NOS (7%), nausea (10%), CPK ↑ (5%), bilirubin ↑ (5%) Tx-related deaths: n=4 Effect of Dex:
|
| Garcia-Carbonero et al (2005)4 | Open-label, single-arm, multicenter study in chemo-naïve pts with advanced, unresectable STS (N=36) |
| Median f/u: 25 mo Primary Endpoint:
Additional Endpoints:
| Grade 3-4 AEs: Transient ALT ↑ (36%), transient AST ↑ (34%), neutropenia (33%), leukopenia (22%), nausea (14%), vomiting (14%), fatigue (11%), CPK ↑ (3%), anemia (3%) Additional AEs: Grade 1-2 AP ↑ (39%), grade 1-2 bilirubin ↑ (6%) D/C due to tx-related AEs: 2 pts (persistent AP ↑ on day 35) |
| Garcia-Carbonero et al (2004)2 | Open-label, single-arm, multicenter study in pts with previously treated recurrent or metastatic STS (N=36) |
| Median f/u: 38.6 mo Primary Endpoint:
Additional Endpoints:
| Grade 3-4 AEs: Leukopenia (43%), neutropenia (34%), AST ↑ (26%), ALT ↑ (20%), thrombocytopenia (17%), anemia (9%), febrile neutropenia (6%), nausea (6%), bilirubin ↑ (3%), CPK ↑ (3%), vomiting (3%) |
| Monk et al (2012)3 | Open-label, single-arm, 2stage study in chemo-naïve pts with advanced uterine LMS (N=20) |
| Median number of cycles: 2 (range, 2-29) Primary Endpoint:
Additional Endpoints:
| Grade 3-4 AEs: Neutropenia (n=16; 1 infection); leukopenia (n=11); thrombocytopenia (n=3); metabolic events (n=3); ALT ↑ (n=2); anemia (n=1); gastrointestinal and vascular events (n=1 each) W/D's due to AEs: n=1 |
| aStudies in each section are presented by descending number of patients. bYONDELIS was administered via a central venous line. Abbreviations: AEs, adverse events; ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; chemo, chemotherapy; CPK, creatine phosphokinase; CR, complete response; D/C, discontinue or discontinuation; Dex, dexamethasone; DOR, duration of response; DOX, doxorubicin; EFT, Ewing's family tumor; f/u, follow-up; hrs, hours; IV, intravenous; LMS, leiomyosarcoma; min, minutes; mo, months; MR, minor response; NOS, not otherwise specified; ORR, overall response rate; OS, overall survival; OTS, osteosarcoma; PD, progressive disease; PFS, progression-free survival; PL, placebo; po, orally; PR, partial response; pts, patients; q, every; Q3W, every 3 weeks; SAEs, serious adverse events; SD, stable disease; STS, soft tissue sarcoma; TTP, time to progression; tx, treatment; w/, with; w/d, withdrawal. | ||||
Grosso et al (2006)5 evaluated the effect of dexamethasone premedication on the safety of YONDELIS in 54 previously-treated patients with advanced sarcoma. Patients received YONDELIS on a compassionate basis at a dose of 1000-1650 μg/m2, either as a 3-hour (n=15) or 24-hour infusion (n=39) via central venous access every 3 weeks. Routine antiemetic premedication included IV dexamethasone (8-20 mg) and ondansetron. The initial 23 patients received YONDELIS with routine antiemetic prophylaxis alone, which did not include steroids on the day before therapy, but only on day 0 and possibly on day +1 (Group 1). Thirty-one patients received YONDELIS with steroid premedication (dexamethasone 4 mg orally twice daily) on the day before the YONDELIS infusion (Group 2). Hepatic and hematologic toxicity was reduced in the group who received dexamethasone premedication compared with the group who did not, as shown in the table below.
| Patients | Cycles | |||
|---|---|---|---|---|
| YONDELIS + Dexamethasone Premedication (n=31) n (%) | YONDELIS without Dexamethasone Premedication (n=23) n (%) | YONDELIS + Dexamethasone Premedication (n=31) n (%) | YONDELIS without Dexamethasone Premedication (n=23) n (%) | |
| Grade 3/4 AST/ALT elevation | 1 (3%) | 16 (70%) | 1 (<1%) | 23 (34%) |
| Grade 3/4 neutropenia | 3 (10%) | 9 (39%) | 3 (2%) | 16 (23%) |
| Grade 3/4 thrombo-cytopenia | - | 8 (35%) | - | 17 (25%) |
| Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase. | ||||
| 1 | YONDELIS (trabectedin) [Prescribing Information]. Horsham, PA: Janssen Products, LP; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 |
Would you like to clear and leave your conversation? Message history will be lost.